Page last updated: 2024-11-06

clanobutin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

clanobutin: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID35378
CHEMBL ID2107589
CHEBI ID135471
SCHEMBL ID667903
MeSH IDM0071393

Synonyms (38)

Synonym
brn 2172135
clanobutinum [inn-latin]
n-(p-chlorbenzoyl)-gamma-(p-anisidino)-buttersaeure [german]
clanobutin [inn]
4-((4-chlorobenzoyl)(4-methoxyphenyl)amino)butanoic acid
butanoic acid, 4-((4-chlorobenzoyl)(4-methoxyphenyl)amino)-
bykahepar
b 6518
n-(p-chlorobenzoyl)-gamma-(p-anisidino)butyric acid
clanobutina [inn-spanish]
einecs 250-232-3
clanobutine
4-(p-chloro-n-(p-methoxyphenyl)benzamido)butyric acid
butyric acid, 4-(p-chloro-n-(p-methoxyphenyl)benzamido)-
clanobutine [inn-french]
30544-61-7
bykahepar [veterinary] (tn)
D07708
clanobutin (inn)
clanobutin
CHEBI:135471
4-(n-(4-chlorobenzoyl)-4-methoxyanilino)butanoic acid
CHEMBL2107589
clanobutina
w6y945055s ,
n-(p-chlorbenzoyl)-gamma-(p-anisidino)-buttersaeure
clanobutinum
unii-w6y945055s
AKOS015896130
SCHEMBL667903
clanobutin [mi]
n-(p-chlorobenzoyl)-4-(p-anisidino)butyric acid
n-(p-chlorobenzoyl)-4-(p-anisidino)-butyric acid
VUPBWNXFSDRWJE-UHFFFAOYSA-N
DTXSID10184628
butanoic acid, 4-[(4-chlorobenzoyl)(4-methoxyphenyl)amino]-
BCP15654
Q27292414

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Rats treated with clanobutine had only the one-third of ulcers compared with the untreated animals."( [On the influence of clanobutine on the formation of restraint ulcer in rats (author's transl)].
Gerlach, U; Hengst, K; Hossdorf, T; Wagner, H, 1979
)
0.9
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzamides
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (73.33)18.7374
1990's3 (20.00)18.2507
2000's0 (0.00)29.6817
2010's1 (6.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.70 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index37.47 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]